Transgene : ASCO 2018: Premiers résultats encourageants pour Pexa-Vec !
>Pexa-Vec semble avoir une activité antitumorale marquée - Transgene est attendu cette année sur de nombreux premiers résultats cliniques suite à son refocus stratégique sur l’immunothérapie entamé il y a quelques années. A l’ASCO, Transgene dévoile des premiers résultats encourageants pour l’un des pans de sa stratégie : les virus oncolytiques. Les premiers résultats communiqués à l’ASCO ont montré que l’injection intraveineuse de Pexa-Vec induit une stimulation de l...Transgene is a biopharmaceutical company that designs and develops immunotherapy and virotherapy products for the treatment of cancers and infectious diseases. Co. is developing three anti-cancer products that are in clinical trials: (cancer of the lungs, liver and oropharynx); two anti-infectious immunotherapy products also in clinical trials: (hepatitis B and C). Co. also has products in the pre-clinical development stage. Co. operates in a single business segment, the research and development of therapeutic vaccines and immunotherapy products. Co. does not have any products on the market. Substantially all of its operations are conducted in France.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.